Trade Biomerieux - BIM CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.45 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.022082% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.00014% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | EUR | ||||||||
Margin | 5% | ||||||||
Stock exchange | France | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Biomerieux SA ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 100.6 |
Open* | 100.5 |
1-Year Change* | 1.77% |
Day's Range* | 98.8 - 100.5 |
52 wk Range | 84.54-102.60 |
Average Volume (10 days) | 66.45K |
Average Volume (3 months) | 1.97M |
Market Cap | 11.50B |
P/E Ratio | 29.86 |
Shares Outstanding | 118.12M |
Revenue | 3.70B |
EPS | 3.26 |
Dividend (Yield %) | 0.87449 |
Beta | 0.03 |
Next Earnings Date | Mar 6, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 5, 2023 | 99.40 | -0.60 | -0.60% | 100.00 | 100.70 | 98.65 |
Dec 4, 2023 | 100.60 | 0.60 | 0.60% | 100.00 | 101.35 | 99.90 |
Dec 1, 2023 | 100.35 | 1.55 | 1.57% | 98.80 | 100.50 | 98.50 |
Nov 30, 2023 | 98.60 | 0.20 | 0.20% | 98.40 | 98.85 | 96.90 |
Nov 29, 2023 | 98.75 | 0.35 | 0.36% | 98.40 | 99.40 | 98.05 |
Nov 28, 2023 | 98.70 | 0.60 | 0.61% | 98.10 | 98.75 | 97.40 |
Nov 27, 2023 | 98.40 | 0.05 | 0.05% | 98.35 | 99.25 | 98.15 |
Nov 24, 2023 | 98.10 | 0.50 | 0.51% | 97.60 | 98.20 | 97.00 |
Nov 23, 2023 | 98.10 | 1.45 | 1.50% | 96.65 | 98.15 | 96.20 |
Nov 22, 2023 | 96.80 | 0.85 | 0.89% | 95.95 | 97.00 | 95.25 |
Nov 21, 2023 | 95.55 | -0.05 | -0.05% | 95.60 | 95.85 | 94.95 |
Nov 20, 2023 | 95.70 | 0.30 | 0.31% | 95.40 | 96.10 | 94.15 |
Nov 17, 2023 | 95.80 | 0.50 | 0.52% | 95.30 | 96.60 | 95.30 |
Nov 16, 2023 | 95.70 | -0.80 | -0.83% | 96.50 | 96.95 | 95.65 |
Nov 15, 2023 | 96.55 | -0.25 | -0.26% | 96.80 | 98.00 | 96.00 |
Nov 14, 2023 | 97.20 | 3.10 | 3.29% | 94.10 | 97.90 | 93.90 |
Nov 13, 2023 | 93.80 | 1.05 | 1.13% | 92.75 | 94.05 | 92.50 |
Nov 10, 2023 | 92.55 | -0.35 | -0.38% | 92.90 | 93.25 | 91.35 |
Nov 9, 2023 | 93.20 | 0.70 | 0.76% | 92.50 | 93.90 | 92.45 |
Nov 8, 2023 | 92.90 | 0.80 | 0.87% | 92.10 | 93.65 | 92.10 |
Biomerieux Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, March 6, 2024 | ||
Time (UTC) 07:30 | Country FR
| Event Full Year 2023 Biomerieux SA Earnings Release Full Year 2023 Biomerieux SA Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 3589.1 | 3376.2 | 3118.2 | 2674.8 | 2421.3 |
Revenue | 3589.1 | 3376.2 | 3118.2 | 2674.8 | 2421.3 |
Cost of Revenue, Total | 1580.4 | 1375.4 | 1364.5 | 1208.2 | 1119 |
Gross Profit | 2008.7 | 2000.8 | 1753.7 | 1466.6 | 1302.3 |
Total Operating Expense | 3001.9 | 2591.3 | 2566 | 2304.1 | 2075.2 |
Selling/General/Admin. Expenses, Total | 954.7 | 815.6 | 789.3 | 749.8 | 643.1 |
Research & Development | 446.6 | 385.8 | 398.8 | 374.3 | 326.9 |
Depreciation / Amortization | 76.6 | 59.7 | 17.5 | 17.9 | 17.5 |
Unusual Expense (Income) | -0.6 | 0.6 | |||
Other Operating Expenses, Total | -56.4 | -44.6 | -4.7 | -46.1 | -31.3 |
Operating Income | 587.2 | 784.9 | 552.2 | 370.7 | 346.1 |
Interest Income (Expense), Net Non-Operating | -4.3 | -11.7 | -29.1 | -23.8 | -26.7 |
Other, Net | -2.3 | 1.3 | 1.2 | 0.7 | -1.9 |
Net Income Before Taxes | 580.6 | 774.5 | 524.3 | 347.6 | 317.5 |
Net Income After Taxes | 440.5 | 598.9 | 402.8 | 269.8 | 252.4 |
Minority Interest | 11.8 | 2.9 | 1.7 | 3.1 | 1.1 |
Equity In Affiliates | 0 | -0.7 | -0.2 | 0 | 0.2 |
Net Income Before Extra. Items | 452.3 | 601.1 | 404.3 | 272.9 | 253.7 |
Net Income | 452.3 | 601.1 | 404.3 | 272.9 | 253.7 |
Total Adjustments to Net Income | 0.1 | 0 | 0.1 | -0.1 | 2.8 |
Income Available to Common Excl. Extra. Items | 452.4 | 601.1 | 404.4 | 272.8 | 256.5 |
Income Available to Common Incl. Extra. Items | 452.4 | 601.1 | 404.4 | 272.8 | 256.5 |
Diluted Net Income | 452.4 | 601.1 | 404.4 | 272.8 | 256.5 |
Diluted Weighted Average Shares | 118.441 | 118.893 | 118.592 | 118.609 | 118.203 |
Diluted EPS Excluding Extraordinary Items | 3.81964 | 5.05579 | 3.41 | 2.3 | 2.17 |
Dividends per Share - Common Stock Primary Issue | 0.85 | 0.85 | 0.62 | 0.19 | 0.35 |
Diluted Normalized EPS | 3.81964 | 5.05189 | 3.41389 | 2.3 | 2.17 |
Dilution Adjustment | 0 |
Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
---|---|---|---|---|---|
Total revenue | 1770.1 | 1931.1 | 1658 | 1802 | 1574.2 |
Revenue | 1770.1 | 1931.1 | 1658 | 1802 | 1574.2 |
Cost of Revenue, Total | 770.9 | 860.4 | 720 | 721.6 | 659.2 |
Gross Profit | 999.2 | 1070.7 | 938 | 1080.4 | 915 |
Total Operating Expense | 1562.3 | 1641 | 1360.9 | 1383.5 | 1208.4 |
Selling/General/Admin. Expenses, Total | 502.1 | 514.4 | 440.3 | 436.9 | 379.6 |
Research & Development | 226.5 | 239.3 | 207.3 | 204.8 | 181.5 |
Depreciation / Amortization | 83.6 | 51.7 | 24.9 | 44.6 | 8.3 |
Other Operating Expenses, Total | -20.8 | -24.8 | -31.6 | -24.4 | -20.2 |
Operating Income | 207.8 | 290.1 | 297.1 | 418.5 | 365.8 |
Interest Income (Expense), Net Non-Operating | 0.9 | 2.8 | -7.1 | -4.7 | -7 |
Other, Net | -0.4 | -3.8 | 1.5 | 1.3 | 0.6 |
Net Income Before Taxes | 208.3 | 289.1 | 291.5 | 415.1 | 359.4 |
Net Income After Taxes | 138.7 | 214.2 | 226.3 | 322 | 276.9 |
Minority Interest | 22.9 | 10 | 1.8 | 1.8 | 1.1 |
Equity In Affiliates | 0 | 0 | 0 | 0.2 | -0.9 |
Net Income Before Extra. Items | 161.6 | 224.2 | 228.1 | 324 | 277.1 |
Net Income | 161.6 | 224.2 | 228.1 | 324 | 277.1 |
Income Available to Common Excl. Extra. Items | 161.6 | 224.4 | 228 | 324 | 277.1 |
Income Available to Common Incl. Extra. Items | 161.6 | 224.4 | 228 | 324 | 277.1 |
Diluted Net Income | 161.6 | 224.4 | 228 | 324 | 277.1 |
Diluted Weighted Average Shares | 118.613 | 118.533 | 118.349 | 119.1 | 118.927 |
Diluted EPS Excluding Extraordinary Items | 1.36241 | 1.89315 | 1.92651 | 2.7204 | 2.33 |
Dividends per Share - Common Stock Primary Issue | 0 | 0.85 | 0 | 0.85 | 0 |
Diluted Normalized EPS | 1.36241 | 1.89315 | 1.92651 | 2.7204 | 2.33 |
Total Adjustments to Net Income | 0.2 | -0.1 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 2216.7 | 2184.6 | 1661.6 | 1438.5 | 1314.4 |
Cash and Short Term Investments | 552.6 | 803.5 | 389.2 | 275 | 288.3 |
Cash | 401.7 | 547.1 | 313.5 | 241 | 239.9 |
Cash & Equivalents | 150.9 | 256.4 | 75.7 | 34 | 48.4 |
Total Receivables, Net | 926.9 | 761 | 730.4 | 668.8 | 607.3 |
Accounts Receivable - Trade, Net | 740.1 | 590.6 | 597.9 | 552.1 | 491.8 |
Total Inventory | 737.2 | 620 | 541.9 | 494.7 | 418.8 |
Other Current Assets, Total | 0.1 | 0.1 | |||
Total Assets | 5186.6 | 4605 | 3927.8 | 3781.9 | 3501.6 |
Property/Plant/Equipment, Total - Net | 1369.9 | 1224.8 | 1068.6 | 1025.2 | 899.1 |
Property/Plant/Equipment, Total - Gross | 2703.9 | 2447.7 | 2173.3 | 2100.9 | 1899.4 |
Accumulated Depreciation, Total | -1334.1 | -1222.7 | -1104.7 | -1075.7 | -1000.5 |
Goodwill, Net | 812.5 | 669.5 | 629.4 | 652.5 | 619 |
Intangibles, Net | 625 | 411.5 | 430.7 | 508.4 | 507.2 |
Long Term Investments | 71.2 | 62 | 39.9 | 31.7 | 59.2 |
Note Receivable - Long Term | 19.8 | 10.7 | 10.4 | 8 | |
Other Long Term Assets, Total | 71.5 | 52.6 | 86.9 | 115.2 | 94.7 |
Total Current Liabilities | 1131.1 | 955.7 | 923.8 | 1170.1 | 796.3 |
Accounts Payable | 269.4 | 239.5 | 207.1 | 211.9 | 179.7 |
Accrued Expenses | 372.6 | 327.4 | 283.3 | 262.4 | |
Notes Payable/Short Term Debt | 23.9 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 163.1 | 99.7 | 128.9 | 438.6 | 129.1 |
Other Current Liabilities, Total | 302.1 | 616.5 | 260.4 | 236.3 | 225.1 |
Total Liabilities | 1582.4 | 1492.8 | 1496.7 | 1578 | 1572.8 |
Total Long Term Debt | 318.4 | 362.8 | 352.4 | 153.7 | 524.9 |
Long Term Debt | 224.7 | 362.8 | 352.4 | 153.7 | 524.9 |
Deferred Income Tax | 53 | 60.3 | 105.8 | 141.2 | 130.5 |
Minority Interest | 38.7 | 51.4 | 50.2 | 50.7 | 74.1 |
Other Liabilities, Total | 41.2 | 62.6 | 64.5 | 62.3 | 47 |
Total Equity | 3604.2 | 3112.2 | 2431.1 | 2203.9 | 1928.8 |
Common Stock | 12 | 12 | 12 | 12 | 12 |
Additional Paid-In Capital | 3062.2 | 2532.1 | 2204.7 | 1933.4 | 1712.2 |
Retained Earnings (Accumulated Deficit) | 410.4 | 542.5 | 344.7 | 207.9 | 210.1 |
Treasury Stock - Common | -36 | -10.3 | -23 | -3.9 | -32.8 |
Other Equity, Total | 155.6 | 35.9 | -107.3 | 54.5 | 27.3 |
Total Liabilities & Shareholders’ Equity | 5186.6 | 4605 | 3927.8 | 3781.9 | 3501.6 |
Total Common Shares Outstanding | 118 | 118.282 | 118.16 | 118.324 | 117.819 |
Capital Lease Obligations | 93.7 |
Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
---|---|---|---|---|---|
Total Current Assets | 2152.7 | 2216.7 | 2058.4 | 2184.6 | 1798.7 |
Cash and Short Term Investments | 423 | 552.6 | 524.2 | 803.5 | 493.2 |
Cash | 320.2 | 401.7 | 365.6 | 803.5 | 363.3 |
Cash & Equivalents | 102.8 | 150.9 | 158.6 | 129.9 | |
Total Receivables, Net | 888.9 | 926.9 | 825.7 | 761 | 694.5 |
Accounts Receivable - Trade, Net | 657.7 | 740.1 | 624.2 | 590.6 | 542.4 |
Total Inventory | 840.9 | 737.2 | 708.5 | 620 | 611 |
Total Assets | 5030.9 | 5186.6 | 5041.2 | 4605 | 4157.2 |
Property/Plant/Equipment, Total - Net | 1392 | 1369.9 | 1314.4 | 1224.8 | 1135.2 |
Property/Plant/Equipment, Total - Gross | 2782.4 | 2703.9 | 2620.7 | 2447.7 | 2306.1 |
Accumulated Depreciation, Total | -1390.4 | -1334 | -1306.2 | -1222.7 | -1170.8 |
Goodwill, Net | 734.4 | 812.5 | 877.5 | 669.5 | 642.4 |
Intangibles, Net | 592.5 | 625 | 667.5 | 411.5 | 426.8 |
Long Term Investments | 89.2 | 91 | 48 | 62 | 56.6 |
Other Long Term Assets, Total | 70.1 | 71.5 | 75.4 | 52.6 | 97.5 |
Total Current Liabilities | 980.7 | 1131.1 | 1020.7 | 955.7 | 857.9 |
Accounts Payable | 243.5 | 269.4 | 243.4 | 239.5 | 199.1 |
Notes Payable/Short Term Debt | 22.4 | 23.9 | 11 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 138.2 | 163.1 | 215 | 99.7 | 163.2 |
Other Current Liabilities, Total | 576.6 | 674.7 | 551.3 | 616.5 | 495.6 |
Total Liabilities | 1403.6 | 1582.4 | 1572.2 | 1492.8 | 1459 |
Total Long Term Debt | 330.1 | 318.4 | 365.7 | 362.8 | 361.5 |
Long Term Debt | 231.7 | 224.7 | 272 | 362.8 | 361.5 |
Deferred Income Tax | 33.9 | 53 | 97.2 | 60.3 | 124.7 |
Minority Interest | 14.2 | 38.7 | 44.9 | 51.4 | 50.8 |
Other Liabilities, Total | 44.7 | 41.2 | 43.7 | 62.6 | 64.1 |
Total Equity | 3627.3 | 3604.2 | 3469 | 3112.2 | 2698.2 |
Common Stock | 12 | 12 | 12.2 | 12 | 12 |
Additional Paid-In Capital | 3416.3 | 3062.2 | 3174.3 | 2532.1 | 2528.8 |
Retained Earnings (Accumulated Deficit) | 120.2 | 410.4 | 183.5 | 542.5 | 219.5 |
Treasury Stock - Common | -20.9 | -36 | -152.3 | -10.3 | -16.6 |
Other Equity, Total | 99.7 | 155.6 | 251.3 | 35.9 | -45.5 |
Total Liabilities & Shareholders’ Equity | 5030.9 | 5186.6 | 5041.2 | 4605 | 4157.2 |
Total Common Shares Outstanding | 118.124 | 118 | 119.507 | 118.282 | 118.095 |
Other Current Assets, Total | -0.1 | 0.1 | |||
Capital Lease Obligations | 98.4 | 93.7 | 93.7 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 440.5 | 598.2 | 402.7 | 269.7 | 255.6 |
Cash From Operating Activities | 475.1 | 824.7 | 582.8 | 407.9 | 399.7 |
Cash From Operating Activities | 67 | 58.8 | 210.8 | 189.5 | 177 |
Non-Cash Items | 264.8 | 176.7 | 159 | 45.5 | 12.3 |
Cash Taxes Paid | 223.5 | 185.4 | 115.9 | 81.6 | 66.5 |
Cash Interest Paid | |||||
Changes in Working Capital | -297.2 | -9 | -189.7 | -96.8 | -45.2 |
Cash From Investing Activities | -528.1 | -307.3 | -265.2 | -282.2 | -413.1 |
Capital Expenditures | -286.7 | -290.1 | -277.5 | -272.5 | -226.4 |
Other Investing Cash Flow Items, Total | -241.4 | -17.2 | 12.3 | -9.7 | -186.7 |
Cash From Financing Activities | -244.2 | -140.6 | -176.2 | -133.9 | 43 |
Financing Cash Flow Items | -0.1 | -2.4 | -23.4 | 0 | |
Total Cash Dividends Paid | -101.2 | -73.1 | -22.5 | -41.3 | -40.2 |
Issuance (Retirement) of Stock, Net | -157.2 | -17.4 | -16.8 | 0 | -22.3 |
Issuance (Retirement) of Debt, Net | 14.3 | -50.1 | -134.5 | -69.2 | 105.5 |
Foreign Exchange Effects | 38.7 | 39.2 | -34.1 | -6.1 | -11.8 |
Net Change in Cash | -258.5 | 416 | 107.3 | -14.3 | 17.8 |
Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
---|---|---|---|---|
Net income/Starting Line | 440.5 | 226.2 | 598.2 | 276 |
Cash From Operating Activities | 475.1 | 150.9 | 824.7 | 285.8 |
Cash From Operating Activities | 67 | 100.4 | 58.8 | 97.2 |
Non-Cash Items | 264.8 | -27.4 | 176.7 | -66.4 |
Cash Taxes Paid | 223.5 | 145.4 | 185.4 | 98.1 |
Changes in Working Capital | -297.2 | -148.3 | -9 | -21 |
Cash From Investing Activities | -528.1 | -352.3 | -307.3 | -143.4 |
Capital Expenditures | -286.7 | -152.8 | -290.1 | -143.5 |
Other Investing Cash Flow Items, Total | -241.4 | -199.5 | -17.2 | 0.1 |
Cash From Financing Activities | -244.2 | -127.8 | -140.6 | -73.8 |
Total Cash Dividends Paid | -101.2 | -101.2 | -73.1 | -73.1 |
Issuance (Retirement) of Stock, Net | -157.2 | -111.3 | -17.4 | -2.5 |
Issuance (Retirement) of Debt, Net | 14.3 | 84.8 | -50.1 | 1.8 |
Foreign Exchange Effects | 38.7 | 55.2 | 39.2 | 12.8 |
Net Change in Cash | -258.5 | -274 | 416 | 81.4 |
Financing Cash Flow Items | -0.1 | -0.1 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Mérieux Family | Other Insider Investor | 58.9047 | 69720270 | 0 | 2022-12-13 | |
Dassault Family | Other Insider Investor | 4.5964 | 5440410 | 0 | 2022-12-13 | LOW |
Sofina S.A. | Investment Advisor/Hedge Fund | 1.7293 | 2046857 | 0 | 2022-12-13 | |
Oddo BHF Asset Management S.A.S | Investment Advisor/Hedge Fund | 1.356 | 1604994 | 44775 | 2023-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.0518 | 1244911 | 5637 | 2023-09-30 | LOW |
Candriam Luxembourg S.A. | Investment Advisor | 0.877 | 1037976 | -63467 | 2023-09-30 | MED |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.853 | 1009582 | -23564 | 2022-12-31 | LOW |
Biomérieux Employees | Corporation | 0.7268 | 860200 | 0 | 2022-12-13 | |
DNCA Investments | Investment Advisor | 0.6872 | 813349 | 178315 | 2023-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.6085 | 720178 | -7576 | 2023-09-30 | LOW |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.5764 | 682229 | 3853 | 2023-09-30 | LOW |
Devon Equity Management Ltd. | Investment Advisor | 0.5669 | 670995 | 0 | 2023-09-30 | LOW |
La Financière de l'Echiquier | Investment Advisor | 0.5363 | 634787 | -66095 | 2023-09-30 | MED |
Capital Research Global Investors | Investment Advisor | 0.5084 | 601782 | -4401 | 2023-09-30 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.4926 | 583078 | 6150 | 2023-09-30 | LOW |
CPR Asset Management | Investment Advisor | 0.4043 | 478520 | -2462 | 2023-08-31 | MED |
AXA Investment Managers Paris | Investment Advisor/Hedge Fund | 0.3672 | 434670 | -4318 | 2023-08-31 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.3641 | 430947 | 2514 | 2023-08-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3628 | 429455 | 1 | 2023-09-30 | LOW |
Credit Mutuel Asset Management | Investment Advisor | 0.3119 | 369132 | 3000 | 2023-08-31 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Biomerieux Company profile
About BioMerieux SA
Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, BioMerieux SA revenues increased 8% to EUR3.38B. Net income applicable to common stockholders increased 49% to EUR601.1M. Revenues reflect Microbiology segment increase of 12% to EUR1.06B, Molecular Biology segment increase of 5% to EUR1.27B, Europe & Middle East & Africa (EMEA) (Region) segment increase of 10% to EUR1.12B, America segment increase of 5% to EUR1.67B.
Equity composition
9/2017, 3-for-1 stock split (Factor: 3).
Industry: | Laboratory Diagnostic & Testing Substances |
376, chemin de l'Orme
CRAPONNE
AUVERGNE-RHONE-ALPES 69280
FR
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com